JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB97777

Anti-Mad2L1 antibody

4

(1 Review)

|

(12 Publications)

Rabbit Polyclonal Mad2L1 antibody. Suitable for IP, WB, IHC-P, ICC/IF and reacts with Human, Rat samples. Cited in 12 publications. Immunogen corresponding to Synthetic Peptide within Human MAD2L1 aa 150 to C-terminus.

View Alternative Names

MAD2, MAD2L1, Mitotic spindle assembly checkpoint protein MAD2A, HsMAD2, Mitotic arrest deficient 2-like protein 1, MAD2-like protein 1

10 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Mad2L1 antibody (AB97777)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Mad2L1 antibody (AB97777)

Immunohistochemical analysis of paraffin-embedded human a549 xenograft tissue stained for MAD2L1 protein at cytoplasm and nucleus with ab97777 at a 1/250 dilution.

Antigen retrieval : EDTA based buffer, (pH 8.0), 15min

Immunocytochemistry/ Immunofluorescence - Anti-Mad2L1 antibody (AB97777)
  • ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-Mad2L1 antibody (AB97777)

Immunofluorescence analysis of Mad2L1 in Human osteosarcoma cell line U2OS, using ab97777 at 1/1000 dilution.
1 : Mad2L1
2 : ACA
3 : merged with DAPI
Cells were fixed with 4% PFA/PBS for 15min, RT and blocked with 2.5% BSA/PBS.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Mad2L1 antibody (AB97777)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Mad2L1 antibody (AB97777)

Immunohistochemical analysis of Mad2L1 in paraffin embedded DLD-1 xenograft, using ab97777 at a 1/500 dilution.

Immunoprecipitation - Anti-Mad2L1 antibody (AB97777)
  • IP

Supplier Data

Immunoprecipitation - Anti-Mad2L1 antibody (AB97777)

Immunoprecipitation of MAD2L1 protein from 293T whole cell extracts using 5 µg of ab97777. Western blot analysis was performed using ab97777.

All lanes:

Immunoprecipitation - Anti-Mad2L1 antibody (ab97777) at 5 µg

Lane 1:

293T whole cell extracts (Input)

Lane 2:

293T whole cell extracts with control IgG (-)

Lane 3:

293T whole cell extracts (+)

Secondary

All lanes:

Anti-Rabbit IgG

Predicted band size: 24 kDa

false

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Mad2L1 antibody (AB97777)
  • IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Mad2L1 antibody (AB97777)

Immunohistochemical analysis of paraffin-embedded rat fore brain tissue stained for MAD2L1 protein at nucleus with ab97777 at a 1/500 dilution.

Antigen retrieval : EDTA based buffer, (pH 8.0), 15min

Western blot - Anti-Mad2L1 antibody (AB97777)
  • WB

Supplier Data

Western blot - Anti-Mad2L1 antibody (AB97777)

Samples were separated by 12% SDS-PAGE.

All lanes:

Western blot - Anti-Mad2L1 antibody (ab97777) at 1/1000 dilution

Lane 1:

293T whole cell extracts at 30 µg

Lane 2:

MAD2L1 shRNA transfected 293T whole cell extracts at 30 µg

Secondary

All lanes:

HRP-conjugated anti-rabbit IgG antibody

Predicted band size: 24 kDa

false

Western blot - Anti-Mad2L1 antibody (AB97777)
  • WB

Supplier Data

Western blot - Anti-Mad2L1 antibody (AB97777)

Samples were separated by 12% SDS-PAGE.

All lanes:

Western blot - Anti-Mad2L1 antibody (ab97777) at 1/1000 dilution

Lane 1:

Jurkat whole cell extracts at 30 µg

Lane 2:

Raji whole cell extracts at 30 µg

Lane 3:

NCI-H929 whole cell extracts at 30 µg

Secondary

All lanes:

HRP-conjugated anti-rabbit IgG antibody

Predicted band size: 24 kDa

false

Western blot - Anti-Mad2L1 antibody (AB97777)
  • WB

Unknown

Western blot - Anti-Mad2L1 antibody (AB97777)

All lanes:

Western blot - Anti-Mad2L1 antibody (ab97777) at 1/1000 dilution

Lane 1:

HepG2 whole cell lysate at 30 µg

Lane 2:

MOLT4 whole cell lysate at 30 µg

Lane 3:

Raji whole cell lysate at 30 µg

Predicted band size: 24 kDa

false

Western blot - Anti-Mad2L1 antibody (AB97777)
  • WB

CiteAb

Western blot - Anti-Mad2L1 antibody (AB97777)

Western Blotting using Anti-Mad2L1 antibodyAnti-Mad2L1 antibody, ab97777. Publication image from Chen, J. et al., 2016, Nat Commun, 26743940. Legend direct from paper.

Cep57 contributes to activation of the spindle assembly checkpoint.(a,b) HeLa cells with 100 nM nocodazole treatment after co-transfection with H2B-RFP and negative control (NC)-, Cep57-, Mad1- or Mad2-siRNA for 48 h. (a) Time-lapse images of HeLa cells. The numbers indicate the time (minutes) after entry into mitosis. Arrowhead, multiple nuclei. Scale bar, 5 µm. (b) Quantification of mitotic duration of HeLa cells from a. Scatter plots show data from three independent experiments. (c) Quantification of mitotic duration of live HeLa cells with 80 nM taxol treatment after co-transfection with H2B-RFP and negative control (NC)-, Cep57-, Mad1- or Mad2-siRNA for 48 h. Scatter plots show data from three independent experiments. (d) Diagram of experimental design. The siRNA-transfected HeLa cells were synchronized by double-thymidine block, and released into nocodazole. (e–g) HeLa cells were treated as in d. (e) After 12 h nocodazole treatment, mitotic cell lysates were used to perform immunoprecipitation (IP) and western blotting assays with the indicated antibodies. WCL, whole-cell lysate. (f) Western blots of the indicated proteins in HeLa cells after the indicated nocodazole (Noc.) treatment time. (g) Quantification of the protein levels of securin and cyclin B1 from (f). The experiment was repeated three times. For b,c and g, data are mean±s.e.m. ****P<0.0001; ***P<0.001; **P<0.01; *P<0.05; NS, not significant (unpaired two-tailed Student's t-test). DIC, differential interference contrast.

false

Western blot - Anti-Mad2L1 antibody (AB97777)
  • WB

CiteAb

Western blot - Anti-Mad2L1 antibody (AB97777)

Western Blotting using Anti-Mad2L1 antibodyAnti-Mad2L1 antibody, ab97777. Publication image from Chen, J. et al., 2016, Nat Commun, 26743940. Legend direct from paper.

Cep57 contributes to activation of the spindle assembly checkpoint.(a,b) HeLa cells with 100 nM nocodazole treatment after co-transfection with H2B-RFP and negative control (NC)-, Cep57-, Mad1- or Mad2-siRNA for 48 h. (a) Time-lapse images of HeLa cells. The numbers indicate the time (minutes) after entry into mitosis. Arrowhead, multiple nuclei. Scale bar, 5 µm. (b) Quantification of mitotic duration of HeLa cells from a. Scatter plots show data from three independent experiments. (c) Quantification of mitotic duration of live HeLa cells with 80 nM taxol treatment after co-transfection with H2B-RFP and negative control (NC)-, Cep57-, Mad1- or Mad2-siRNA for 48 h. Scatter plots show data from three independent experiments. (d) Diagram of experimental design. The siRNA-transfected HeLa cells were synchronized by double-thymidine block, and released into nocodazole. (e–g) HeLa cells were treated as in d. (e) After 12 h nocodazole treatment, mitotic cell lysates were used to perform immunoprecipitation (IP) and western blotting assays with the indicated antibodies. WCL, whole-cell lysate. (f) Western blots of the indicated proteins in HeLa cells after the indicated nocodazole (Noc.) treatment time. (g) Quantification of the protein levels of securin and cyclin B1 from (f). The experiment was repeated three times. For b,c and g, data are mean±s.e.m. ****P<0.0001; ***P<0.001; **P<0.01; *P<0.05; NS, not significant (unpaired two-tailed Student's t-test). DIC, differential interference contrast.

false

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Rat, Human

Applications

IP, IHC-P, ICC/IF, WB

applications

Immunogen

Synthetic Peptide within Human MAD2L1 aa 150 to C-terminus. The exact immunogen used to generate this antibody is proprietary information.

Q13257

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/100 - 1/500", "IP-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500 - 1/3000", "WB-species-notes": "<p></p>", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/100 - 1/1000", "IHCP-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/100 - 1/1000", "ICCIF-species-notes": "<p></p>" }, "Rat": { "IP-species-checked": "guaranteed", "IP-species-dilution-info": "", "IP-species-notes": "", "WB-species-checked": "guaranteed", "WB-species-dilution-info": "", "WB-species-notes": "", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/100 - 1/1000", "IHCP-species-notes": "<p></p>", "ICCIF-species-checked": "guaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Storage buffer
pH: 7 Preservative: 0.01% Thimerosal (merthiolate) Constituents: PBS, 40% Glycerol (glycerin, glycerine)
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Mad2L1 also known as MAD2 or Kirk Mad2 is an important player in the mitotic checkpoint ensuring proper chromosomal segregation during cell division. It acts as a spindle assembly checkpoint protein weighing approximately 24.5 kDa. It is widely expressed in tissues with high proliferative activity including testis thymus and fetal liver. In these locations Mad2L1 binds to other mitotic checkpoint proteins to control the metaphase-anaphase transition.
Biological function summary

Mad2L1 serves as an essential component of the mitotic checkpoint complex. It forms a complex with other proteins such as Mad1 BubR1 and Cdc20 inhibiting the anaphase-promoting complex/cyclosome (APC/C). This interaction prevents the premature separation of sister chromatids by blocking the degradation of securin and cyclin B. These actions ensure that cells do not progress to anaphase until all chromosomes are correctly attached to the mitotic spindle.

Pathways

Mad2L1 interacts with proteins that regulate the spindle assembly checkpoint pathway and the cell cycle. It holds particular prominence within the mitotic spindle assembly checkpoint where it regulates progression from metaphase to anaphase through its interaction with proteins like Cdc20 and BubR1. Mad2L1 also plays a role in the DNA damage response cycle highlighting its importance in maintaining genomic stability.

Mad2L1 shows significant connections with cancer and chromosomal instability syndromes. Overexpression or dysfunction of Mad2L1 can lead to chromosomal instability contributing to carcinogenesis. Studies also suggest associations with BubR1 a protein whose expression frequently correlates with Mad2L1 in various cancers. These connections highlight Mad2L1 as a potential target for therapeutic intervention in oncology.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Component of the spindle-assembly checkpoint that prevents the onset of anaphase until all chromosomes are properly aligned at the metaphase plate (PubMed : 15024386, PubMed : 29162720). In the closed conformation (C-MAD2) forms a heterotetrameric complex with MAD1L1 at unattached kinetochores during prometaphase, the complex recruits open conformation molecules of MAD2L1 (O-MAD2) and then promotes the conversion of O-MAD2 to C-MAD2 (PubMed : 29162720). Required for the execution of the mitotic checkpoint which monitors the process of kinetochore-spindle attachment and inhibits the activity of the anaphase promoting complex by sequestering CDC20 until all chromosomes are aligned at the metaphase plate (PubMed : 10700282, PubMed : 11804586, PubMed : 15024386).
See full target information MAD2L1

Publications (12)

Recent publications for all applications. Explore the full list and refine your search

Chemical biology & drug design 104:e70012 PubMed39487106

2024

Mitotic Arrest Deficient 2 Like 1 Contributes to Colorectal Cancer Cell Migration, Invasion, and Oxaliplatin Resistance Through the Wnt/β-Catenin Pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Xiang Ding,Yonggui Zhou,Linfang He,Hubin Kang,Youwu Wen,Jia Xu,Congbo Zhu,Libing Luo,Qingjun Zeng

The EMBO journal 42:e111587 PubMed37063065

2023

Targeted assembly of ectopic kinetochores to induce chromosome-specific segmental aneuploidies.

Applications

Unspecified application

Species

Unspecified reactive species

Laura Tovini,Sarah C Johnson,Molly A Guscott,Alexander M Andersen,Diana Carolina Johanna Spierings,René Wardenaar,Floris Foijer,Sarah E McClelland

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 9:e2104291 PubMed36031387

2022

Trip13 Depletion in Liver Cancer Induces a Lipogenic Response Contributing to Plin2-Dependent Mitotic Cell Death.

Applications

Unspecified application

Species

Unspecified reactive species

Marcos Rios Garcia,Bettina Meissburger,Jessica Chan,Roldan M de Guia,Frits Mattijssen,Stephanie Roessler,Andreas L Birkenfeld,Nathanael Raschzok,Fabien Riols,Janina Tokarz,Maude Giroud,Manuel Gil Lozano,Goetz Hartleben,Peter Nawroth,Mark Haid,Miguel López,Stephan Herzig,Mauricio Berriel Diaz

Journal of breast cancer 25:178-192 PubMed35775700

2022

Polo-Like Kinase 1 Regulates Chromosomal Instability and Paclitaxel Resistance in Breast Cancer Cells.

Applications

Unspecified application

Species

Unspecified reactive species

Mingji Quan,Yumi Oh,Sung-Yup Cho,Ju Hee Kim,Hyeong-Gon Moon

Cell biology international 46:840-848 PubMed35143103

2022

Targeting of MAD2L1 by miR-515-5p involves the regulation of cell cycle arrest and apoptosis of colorectal cancer cells.

Applications

Unspecified application

Species

Unspecified reactive species

Xiang Ding,Qingyan Fu,Weixing Chen,Linjie Chen,Qingjun Zeng,Sanjun Zhang,Linfang He

Cancer cell international 21:634 PubMed34838000

2021

Bioinformatics prediction and experimental verification identify MAD2L1 and CCNB2 as diagnostic biomarkers of rhabdomyosarcoma.

Applications

Unspecified application

Species

Unspecified reactive species

Tian Xia,Lian Meng,Zhijuan Zhao,Yujun Li,Hao Wen,Hao Sun,Tiantian Zhang,Jingxian Wei,Feng Li,Chunxia Liu

Biochimica et biophysica acta. Molecular cell research 1868:118929 PubMed33310066

2020

Tank Binding Kinase 1 modulates spindle assembly checkpoint components to regulate mitosis in breast and lung cancer cells.

Applications

Unspecified application

Species

Unspecified reactive species

Meenu Maan,Neha Jaiswal Agrawal,Jaya Padmanabhan,Christelle Colin Leitzinger,Yainyrette Rivera-Rivera,Harold I Saavedra,Srikumar P Chellappan

Computational and mathematical methods in medicine 2020:2953598 PubMed33204298

2020

miR-139-5p Inhibits Lung Adenocarcinoma Cell Proliferation, Migration, and Invasion by Targeting MAD2L1.

Applications

Unspecified application

Species

Unspecified reactive species

Jianfeng Li,Xi He,Xiaotang Wu,Xiaohui Liu,Yixiong Huang,Yuchen Gong

Oncogenesis 9:43 PubMed32366853

2020

MiR-93 is related to poor prognosis in pancreatic cancer and promotes tumor progression by targeting microtubule dynamics.

Applications

Unspecified application

Species

Unspecified reactive species

Elena Vila-Navarro,Elena Fernandez-Castañer,Maria Rovira-Rigau,Giulia Raimondi,Maria Vila-Casadesus,Juan Jose Lozano,Philippe Soubeyran,Juan Iovanna,Antoni Castells,Cristina Fillat,Meritxell Gironella

Cell reports 23:852-865 PubMed29669289

2018

USP9X Limits Mitotic Checkpoint Complex Turnover to Strengthen the Spindle Assembly Checkpoint and Guard against Chromosomal Instability.

Applications

Unspecified application

Species

Human

Agnieszka Skowyra,Lindsey A Allan,Adrian T Saurin,Paul R Clarke
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com